Abbvie förvärvar lovande projekt inom psykisk ohälsa

Abbvie köper ett läkemedelsprogram inom mental hälsa i en miljardaffär som ser lite annorlunda än vad som tidigare uppgetts.

ProPharma

KI’s freezer fiasco investigated: A chain of failures

A chain of combined technical and organisational shortcomings caused the freezer breakdown at the Karolinska Institute during the Christmas holidays, destroying...

Scale Up Your Image Analysis

ZEISS arivis Hub for accelerated analysis and faster results.

Nytt samarbete: Chat GPT flyttar in i Lundbecks laboratorier

Den danska läkemedelskoncernen Lundbeck tar hjälp av Open AI för att påskynda forskning och effektivisera arbetet inom hela verksamheten.

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

Bio Europe to Stockholm – ”The Swedish ecosystem is now taking the opportunity”

The international life science conference Bio Europe is coming to Sweden for the first time in November. The conference, whose program takes inspiration from AB...

“We should avoid surgery if we can”

Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about rol...

Smartzoom 100 – The New Digital Microscope for Maximum Efficiency

Free webinar July 1, 9:00-9:45 AM CEST and 5:00-5:45 PM CEST.

Wusson Accelerator AB

Unmatched performance and flexibility in its class

The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

Samuel Lagercrantz: “Companies that do this successfully will take the lead”

The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

Marie Gårdmark: “What to expect from Trump’s second term?”

One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...

Abbvie ryktas överväga miljardförvärv inom mental hälsa

Läkemedelsbolaget Abbvie uppges föra diskussioner om att förvärva Gilgamesh Pharmaceuticals, ett bolag inom mental hälsa, i en affär som ska ligga på omkring en miljard dollar.

SupraCube - In life Science

Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...

Life science trends 2025 – The economy

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...